Abstract: The present invention provides a novel bispecific anti-CD3/CD20 polypeptide complex formulation containing a first antigen-binding portion and a second antigen-binding portion. Specifically, the formulation comprises a liquid formulation and a lyophilized formulation.

Abstract: Provided in the present disclosure are a bifunctional protein which can bind to PD-1 (programmed death receptor-1) and TGF-? (transforming growth factor-?), the medical use of the bifunctional protein, and a preparation method therefor.

Abstract: Provided are a fusion protein targeting PD-L1 and TGF-? and use thereof. The fusion protein is a fusion protein comprising an antibody or antigen-binding fragment that specifically binds to human PD-L1 and a human TGF?RII binding domain. Further provided are a polynucleotide encoding the fusion protein, a host cell containing the polynucleotide, and the use of the fusion protein in the preparation of an anti-tumor drug.

Abstract: A method for preparing a liposome, comprising the step of: (1) dissolving a substance to be encapsulated and phospholipid in an organic solvent to obtain an organic phase, and then mixing the organic phase with water to obtain a liposome feed liquid; (2) extruding the liposome feed liquid obtained in step (1) by means of a polycarbonate membrane; and (3) lyophilizing same.

Abstract: The invention is in the field of antibody formulations, and particularly relates to a pharmaceutical composition of a humanized monoclonal anti-PD-L1 antibody, wherein the pharmaceutical composition comprises 1-150 mg/ml of the humanized monoclonal anti-PD-L1 antibody, a buffer at 3-50 mM, 2-150 mg/ml of an isotonic adjuster/stabilizer and 0.01-0.8 mg/ml of a surfactant, and has a pH of about 4.5-6.8. The formulations prevent antibody aggregates therein from increasing, while enabling better maintenance of the biological binding activity of the antibody for a long time.

Abstract: A method for preparing a liposome, comprising the step of: (1) dissolving a substance to be encapsulated and phospholipid in an organic solvent to obtain an organic phase, and then mixing the organic phase with water to obtain a liposome feed liquid; (2) extruding the liposome feed liquid obtained in step (1) by means of a polycarbonate membrane; and (3) lyophilizing same.